Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDA perspectives on potential microarray-based clinical diagnostics.

Zivana Tezak1, Daya Ranamukhaarachchi, Estelle Russek-Cohen

  • 1Office of In Vitro Diagnostic Device Evaluation and Safety, Center for Devices and Radiological Health, US Food and Drug Administration, Rockville, MD 20850, USA. zivana.tezak@fda.hhhs.gov

Human Genomics
|February 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating Risk Differences Using Large Healthcare Data Networks for Medical Product Post-Market Safety Outcomes in a Distributed Data Setting and Allowing for Active Post-Market Surveillance.

Statistics in medicine·2026
Same author

Resource requirements to accelerate clinical applications of next-generation sequencing and radiomics: workshop commentary and review.

Journal of the National Cancer Institute·2024
Same author

Totality of evidence of the effectiveness of repurposed therapies for COVID-19: Can we use real-world studies alongside randomized controlled trials?

Clinical and translational science·2023
Same author

Platform trials to evaluate the benefit-risk of COVID-19 therapeutics: Successes, learnings, and recommendations for future pandemics.

Contemporary clinical trials·2023
Same author

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023
Same author

A Tutorial on Modern Bayesian Methods in Clinical Trials.

Therapeutic innovation & regulatory science·2023
Same journal

Mutational spectrum of SLC26A4 and SLC26A5 associated with hereditary hearing loss in Moroccan families.

Human genomics·2026
Same journal

National genomic projects in Asia and Africa: a review.

Human genomics·2026
Same journal

Analysis of whole-exome sequencing data from nearly 10,000 Iranian individuals: identification of recessive mitochondrial disease variants and proposal of a population-specific carrier screening panel.

Human genomics·2026
Same journal

Replicating lipid micelles: a feasible precursor to the origin of life and the earliest appearance of genomes.

Human genomics·2026
Same journal

Beckwith-Wiedemann spectrum exhibiting a 46,XY karyotype caused by genome-wide paternal uniparental heterodisomy: a case report.

Human genomics·2026
Same journal

Dynamic responses in the human methylome to exertional heat exhaustion, heat injury, and heat stroke.

Human genomics·2026
See all related articles

The US Food and Drug Administration (FDA) supports novel microarray technologies for medical product evaluation. This paper addresses challenges in translating these nucleic acid microarray devices from research to clinical diagnostics, ensuring safety and effectiveness.

Area of Science:

  • Biotechnology
  • Medical Diagnostics
  • Regulatory Science

Background:

  • The US Food and Drug Administration (FDA) promotes new technologies like microarrays to enhance medical product safety and effectiveness.
  • Microarray technologies offer potential for improved medical treatments, disease prevention, and management strategies.

Purpose of the Study:

  • To discuss the translation of nucleic acid microarray devices from research to in vitro clinical diagnostic use.
  • To address the assurance of safety and effectiveness for these diagnostic devices.

Main Methods:

  • Discussion of general technological aspects of microarrays.
  • Assessment of potential concerns during the transition of microarrays into clinical diagnostic settings.
  • Exploration of approaches for evaluating the performance of microarray-based devices.

Related Experiment Videos

Main Results:

  • Identification of key issues in translating microarray technology for clinical diagnostics.
  • Outlines considerations for regulatory oversight by the Office of In Vitro Diagnostic Device Evaluation and Safety.
  • Highlights the importance of robust performance evaluation for clinical use.

Conclusions:

  • Successful translation of microarray technology requires addressing technological, safety, and regulatory challenges.
  • Effective evaluation strategies are crucial for ensuring the reliability of microarray diagnostics in clinical practice.
  • The FDA's guidance supports the development and implementation of microarrays for public health benefits.